"Vero Cells" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A CELL LINE derived from the kidney of the African green (vervet) monkey, (CERCOPITHECUS AETHIOPS) used primarily in virus replication studies and plaque assays.
| Descriptor ID |
D014709
|
| MeSH Number(s) |
A11.251.210.955 A11.436.955
|
| Concept/Terms |
Vero Cells- Vero Cells
- Cell, Vero
- Cells, Vero
- Vero Cell
|
Below are MeSH descriptors whose meaning is more general than "Vero Cells".
Below are MeSH descriptors whose meaning is more specific than "Vero Cells".
This graph shows the total number of publications written about "Vero Cells" by people in this website by year, and whether "Vero Cells" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 2 | 2 |
| 1995 | 0 | 4 | 4 |
| 1996 | 0 | 3 | 3 |
| 1997 | 0 | 1 | 1 |
| 1999 | 0 | 4 | 4 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 4 | 4 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 3 | 3 |
| 2004 | 0 | 6 | 6 |
| 2005 | 0 | 2 | 2 |
| 2006 | 0 | 4 | 4 |
| 2007 | 0 | 7 | 7 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 2 | 2 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 4 | 4 |
| 2012 | 0 | 5 | 5 |
| 2013 | 0 | 2 | 2 |
| 2014 | 0 | 3 | 3 |
| 2015 | 0 | 4 | 4 |
| 2016 | 0 | 3 | 3 |
| 2017 | 0 | 4 | 4 |
| 2018 | 0 | 10 | 10 |
| 2019 | 0 | 2 | 2 |
| 2020 | 0 | 11 | 11 |
| 2021 | 0 | 15 | 15 |
| 2022 | 0 | 3 | 3 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vero Cells" by people in Profiles.
-
Novel SARS-CoV-2 inhibition properties of the anti-cancer Kang Guan Recipe herbal formula. Cancer Lett. 2024 Nov 01; 604:217198.
-
Glycyrrhizic acid conjugates with amino acid methyl esters target the main protease, exhibiting antiviral activity against wild-type and nirmatrelvir-resistant SARS-CoV-2 variants. Antiviral Res. 2024 07; 227:105920.
-
Developing inhibitory peptides against SARS-CoV-2 envelope protein. PLoS Biol. 2024 Mar; 22(3):e3002522.
-
Autoantibodies neutralizing type I IFNs underlie West Nile virus encephalitis in ~40% of patients. J Exp Med. 2023 09 04; 220(9).
-
A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses. Emerg Microbes Infect. 2022 Dec; 11(1):147-157.
-
Spatio-temporal dynamics of intra-host variability in SARS-CoV-2 genomes. Nucleic Acids Res. 2022 02 22; 50(3):1551-1561.
-
Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2. Nat Commun. 2022 01 20; 13(1):405.
-
Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries. MAbs. 2022 Jan-Dec; 14(1):2002236.
-
High dose of vesicular stomatitis virus-vectored Ebola virus vaccine causes vesicular disease in swine without horizontal transmission. Emerg Microbes Infect. 2021 Dec; 10(1):651-663.
-
An airway organoid-based screen identifies a role for the HIF1a-glycolysis axis in SARS-CoV-2 infection. Cell Rep. 2021 11 09; 37(6):109920.